NASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis $53.33 -1.92 (-3.48%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$53.53 +0.20 (+0.38%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Eton Pharmaceuticals Stock (NASDAQ:ETON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eton Pharmaceuticals alerts:Sign Up Key Stats Today's Range$52.72▼$55.5450-Day Range$40.80▼$64.4352-Week Range$14.27▼$66.37Volume550,924 shsAverage Volume629,743 shsMarket Capitalization$1.52 billionP/E Ratio140.34Dividend YieldN/APrice Target$67.50Consensus RatingBuy Company Overview Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs. Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions. Its products are primarily marketed through the U.S. healthcare system. Founded in 2017 and headquartered in Deer Park, Illinois, Eton has built its business through internal product development, licensing arrangements, and acquisitions of pharmaceutical assets. Sean Brynjelsen, the company’s founder, serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Eton Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreETON MarketRank™: 4.29165566411 of 5 starsEton Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 65th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingEton Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialEton Pharmaceuticals has a consensus price target of $67.50, representing about 26.6% upside from its current price of $53.33.Amount of Analyst CoverageEton Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eton Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth71.68% Earnings GrowthEarnings for Eton Pharmaceuticals are expected to grow by 71.68% in the coming year, from $1.13 to $1.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is 140.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 35.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is 140.34, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 199.17.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 54.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eton Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.68% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 2.94, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eton Pharmaceuticals has recently increased by 18.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.74 News SentimentEton Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eton Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest18 people have searched for ETON on MarketBeat in the last 30 days. This is an increase of 64% compared to the previous 30 days.MarketBeat Follows10 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,809,672.00 in company stock.Percentage Held by Insiders16.49% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions27.86% of the stock of Eton Pharmaceuticals is held by institutions.Read more about Eton Pharmaceuticals' insider trading history. Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETON Stock News HeadlinesEton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film1 hour ago | globenewswire.comEton Pharmaceuticals (NASDAQ:ETON) Stock: Insider David Krempa Sells 4,166 SharesOctober 8, 2026 | americanbankingnews.comTrump's crypto bank just got approvedLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was. Federal regulators granted conditional approval to World Liberty Trust Company… a nationally chartered trust bank tied to the Trump family's crypto venture. Most investors still haven't processed what that means. This bank exists to do one thing. Issue, redeem, custody and back USD1… the stablecoin that has now crossed $4 billion in circulation. The bank isn't operating yet. There are conditions to satisfy first… capital minimums, an audit manager, a sign-off on the business plan. Which means the money hasn't moved yet.October 14 at 1:00 AM | Crypto 101 Media (Ad)Eton Pharmaceuticals (NASDAQ:ETON) Insider David Krempa Sells 4,166 Shares of Company StockOctober 7, 2026 | insidertrades.comAnalyzing Fortress Biotech (NASDAQ:FBIO) and Eton Pharmaceuticals (NASDAQ:ETON)October 4, 2026 | americanbankingnews.comEton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO(R) (miltefosine) CapsulesSeptember 29, 2026 | marketscreener.comMEton Relaunches IMPAVIDO In U.S., Expands Patient Access ProgramsSeptember 28, 2026 | rttnews.comEton Pharmaceuticals Launches IMPAVIDO in the U.S. with Expanded Patient Support and Specialty Pharmacy AccessSeptember 28, 2026 | quiverquant.comQSee More Headlines ETON Stock Analysis - Frequently Asked Questions How have ETON shares performed this year? Eton Pharmaceuticals' stock was trading at $16.91 at the beginning of 2026. Since then, ETON shares have increased by 215.4% and is now trading at $53.33. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its earnings results on Thursday, August, 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.24. The company earned $37.59 million during the quarter, compared to analysts' expectations of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a trailing twelve-month return on equity of 40.13%. Read the conference call transcript. When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO. Who are Eton Pharmaceuticals' major shareholders? Eton Pharmaceuticals' top institutional investors include Juncture Wealth Strategies LLC (0.10%) and Toth Financial Advisory Corp (0.01%). Insiders that own company stock include Opaleye Management Inc, James R Gruber, Paul V Maier, Jennifer Mckie Adams and David Krempa. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Palantir Technologies (PLTR), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Moderna (MRNA). Company Calendar Last Earnings8/13/2026Today10/14/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ETON's financial health is in the Green zone, according to TradeSmith. ETON has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ETON CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees44Year Founded2017Price Target and Rating Average Price Target for Eton Pharmaceuticals$67.50 High Price Target$70.00 Low Price Target$62.00 Potential Upside/Downside+26.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.38 Trailing P/E Ratio140.34 Forward P/E Ratio47.19 P/E GrowthN/ANet Income-$4.60 million Net Margins12.02% Pretax Margin12.07% Return on Equity40.13% Return on Assets12.37% Debt Debt-to-Equity Ratio0.41 Current Ratio1.52 Quick Ratio1.30 Sales & Book Value Annual Sales$79.95 million Price / Sales19.06 Cash Flow$0.01 per share Price / Cash Flow10,659.44 Book Value$0.98 per share Price / Book54.42Miscellaneous Outstanding Shares28,580,000Free Float23,870,000Market Cap$1.52 billion OptionableOptionable Beta0.90 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ETON) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
